{"id":1199,"date":"2022-04-09T09:12:59","date_gmt":"2022-04-09T09:12:59","guid":{"rendered":"https:\/\/www.embl.org\/about\/info\/annual-report\/?page_id=1199"},"modified":"2022-06-07T10:01:50","modified_gmt":"2022-06-07T10:01:50","slug":"start-up-targets-pain-management","status":"publish","type":"page","link":"https:\/\/www.embl.org\/about\/info\/annual-report\/ar2021\/start-up-targets-pain-management","title":{"rendered":"\u200b\u200bStartup targets pain management"},"content":{"rendered":"\n\n  <style>\n    .vf-hero {\n              --vf-hero--bg-image: url('https:\/\/www.embl.org\/about\/info\/annual-report\/wp-content\/uploads\/2022\/05\/20220524_AR2021_banners-scaled.jpg');\n            }\n\n  <\/style>\n<section id=\"\" class=\"vf-hero | vf-u-fullbleed  | vf-u-margin__bottom--0\">\n  <div class=\"vf-hero__content | vf-box | vf-stack vf-stack--400\">\n        <h1 class=\"vf-hero__heading\">\n              Annual Report 2021          <\/h1>\n\n        <p class=\"vf-hero__subheading\">A year of exceptional life science research, training, service, industry collaboration, and integration of European life science research.<\/p>\n    \n    \n      <\/div>\n<\/section>\n<!--\/vf-hero-->\n\n\n\n\n<div class=\"vf-grid | vf-grid__col-3\"><div class=\"vf-grid__col--span-2\"><!--[vf\/content]-->\n<div class=\"vf-content\">\n\n<h1 class=\"wp-block-heading\"><strong><strong><strong>\u200b\u200b<strong><strong>Start-up targets pain management<\/strong><\/strong><\/strong><\/strong><\/strong><\/h1>\n\n\n\n<h2 class=\"wp-block-heading\">EMBL Rome alumnus gets funding to transfer innovative technology and apply gene therapy to potential therapeutics.<\/h2>\n\n\n\n<figure class=\"vf-figure wp-block-image size-full is-style-default\"><img loading=\"lazy\" decoding=\"async\" width=\"1000\" height=\"600\" class=\"vf-figure__image\" src=\"https:\/\/www.embl.org\/about\/info\/annual-report\/wp-content\/uploads\/2022\/04\/20210922_Heppenstall_1000x600px.jpeg\" alt=\"Male scientist working in the lab. On the right side, cross section of a nerve observed with a fluorescent microscope\" class=\"wp-image-646\" srcset=\"https:\/\/www.embl.org\/about\/info\/annual-report\/wp-content\/uploads\/2022\/04\/20210922_Heppenstall_1000x600px.jpeg 1000w, https:\/\/www.embl.org\/about\/info\/annual-report\/wp-content\/uploads\/2022\/04\/20210922_Heppenstall_1000x600px-300x180.jpeg 300w, https:\/\/www.embl.org\/about\/info\/annual-report\/wp-content\/uploads\/2022\/04\/20210922_Heppenstall_1000x600px-768x461.jpeg 768w\" sizes=\"auto, (max-width: 1000px) 100vw, 1000px\" \/><figcaption class=\"vf-figure__caption\">Left: Paul Heppenstall working in the lab. Right: Microscopy image of a nerve with specific nerve cells highlighted in green. Credit: Paul Heppenstall\/EMBL<\/figcaption><\/figure>\n\n\n\n<p>In 2021, Paul Heppenstall took another step forward towards bringing to market a technology he developed at EMBL that could have several potential therapeutic uses.&nbsp;<\/p>\n\n\n\n<p>The former EMBL group leader\u2019s start-up,<a href=\"https:\/\/www.embl.org\/news\/lab-matters\/investing-in-italy-by-translating-embl-expertise-to-the-market\/\"> Borea Therapeutics<\/a>, received<a href=\"https:\/\/www.boreatherapeutics.com\/wp-content\/uploads\/2021\/07\/Borea-PressRelease-30.06.21ITA.pdf\"> seed funding<\/a> from Sofinnova Partners, an Italian fund dedicated to financing innovative biotechnology.<\/p>\n\n\n\n<p>Borea is developing next-generation adenoviral vectors specifically targeted to the central and peripheral nervous system for gene therapy. The modified vectors operate around two key principles: increased efficiency and safety.&nbsp;<\/p>\n\n\n\n<p>Heppenstall moved to Italy in 2008 to study the molecular mechanism underlying pain. The experienced neuroscientist had already led his own research group in Germany. At EMBL Rome, he continued to look for molecular targets to manage pain and itch associated with conditions such as neuropathy, dermatitis, and other genetic skin diseases. There he developed a technology, the basis for Borea Therapeutics, that would allow easier, more efficient delivery of genetic material into mammalian cells, as a strategy to treat neuropathic pain.<\/p>\n\n<\/div>\n<\/div>\n\n\n<div class=\"\"><!--[vf\/content]-->\n<div class=\"vf-content\">\n\n<div style=\"height:163px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<article class=\"vf-profile vf-profile--very-easy vf-profile--medium vf-profile--block | vf-u-margin__bottom--400\">\n\n    <img decoding=\"async\" width=\"155\" height=\"175\" src=\"https:\/\/www.embl.org\/about\/info\/annual-report\/wp-content\/uploads\/2022\/05\/Lucia-Faccio-sml.jpg\" class=\"vf-profile__image\" alt=\"\" loading=\"lazy\" itemprop=\"image\" \/>\n    <h3 class=\"vf-profile__title\" style=\"text-align: center;\">\n                                <\/h3>\n    \n    \n    \n      \n\n    \n<\/article>\n\n\n\n<p class=\"has-text-align-left vf-u-text-color--green vf-text--body vf-text-body--2\"><meta charset=\"utf-8\"><em>\u201cBorea Therapeutics\u2019 technology has the potential to pinpoint specific tissues and cells, which would enable the use of lower doses, making treatment safer and more effective for patients.\u201d <\/em><\/p>\n\n\n\n<p class=\"has-text-align-left  vf-text--body vf-text-body--5\">\u2014 Lucia Faccio, partner at Sofinnova Partners and board member of Borea Therapeutics<\/p>\n\n\n\n<article class=\"vf-profile vf-profile--very-easy vf-profile--medium vf-profile--block | vf-u-margin__bottom--400\">\n\n    <img decoding=\"async\" width=\"155\" height=\"175\" src=\"https:\/\/www.embl.org\/about\/info\/annual-report\/wp-content\/uploads\/2022\/04\/JurgenBauer.jpeg\" class=\"vf-profile__image\" alt=\"\" loading=\"lazy\" itemprop=\"image\" \/>\n    <h3 class=\"vf-profile__title\" style=\"text-align: center;\">\n                                <\/h3>\n    \n    \n    \n      \n\n    \n<\/article>\n\n\n\n<p class=\"has-text-align-left vf-u-text-color--green vf-text--body vf-text-body--2\"><em>\u201cThe formation<\/em><strong> <\/strong><em>of Borea, a startup based on innovations created at EMBL Rome, is a showcase of how excellent teamwork between scientific founders and EMBLEM enables the progression of outstanding science from \u2018bench-to-bedside\u2019.<\/em><meta charset=\"utf-8\"><em>\u201d <\/em><\/p>\n\n\n\n<p class=\"has-text-align-left  vf-text--body vf-text-body--5\"><meta charset=\"utf-8\"><meta charset=\"utf-8\">\u2014 J\u00fcrgen Bauer, <a href=\"https:\/\/embl-em.de\/\">EMBLEM <\/a>Deputy Managing Director<\/p>\n\n\n\n<div class=\"vf-box vf-box--easy vf-box-theme--tertiary | vf-u-margin__bottom--400\">\n      <h3 class=\"vf-box__heading\">\n                Learn more about Borea therapeutics                  <\/h3> \n        <p class=\"vf-box__text\"><!-- wp:list --><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.embl.org\/news\/lab-matters\/investing-in-italy-by-translating-embl-expertise-to-the-market\/\"><span style=\"font-weight: 400;\">Investing in Italy by translating EMBL expertise to the market<\/span><\/a><\/li>\n<\/ul>\n<p class=\"vf-box__text\"><!-- \/wp:list --><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n<style>\n    <\/style>\n\n<section id=\"wp-block-1\">\n  <div class=\"vf-card-container  | vf-u-fullbleed  \n  | vf-u-background-color-ui--grey--light \">\n          <div class=\"vf-section-header | vf-u-margin__bottom--600\">\n        <h2 class=\"vf-section-header__heading\" >\n            <\/h2>\n              <\/div>\n      \n\n<div class=\"embl-grid\"><div class=\"\"><!--[vf\/content]-->\n<div class=\"vf-content\">\n\n<h3 class=\"wp-block-heading\"><a href=\"https:\/\/www.embl.org\/about\/info\/annual-report\/\">Back to Annual report<\/a><\/h3>\n\n<\/div>\n<\/div>\n\n\n<div class=\"\"><!--[vf\/content]-->\n<div class=\"vf-content\">\n\n<article class=\"vf-card vf-card--brand vf-card--bordered vf-u-margin__bottom--800\" default>\n  <img decoding=\"async\" width=\"1024\" height=\"683\" src=\"https:\/\/www.embl.org\/about\/info\/annual-report\/wp-content\/uploads\/2022\/04\/IMG_9436-1024x683.jpg\" class=\"vf-card__image\" alt=\"\" loading=\"lazy\" itemprop=\"image\" srcset=\"https:\/\/www.embl.org\/about\/info\/annual-report\/wp-content\/uploads\/2022\/04\/IMG_9436-1024x683.jpg 1024w, https:\/\/www.embl.org\/about\/info\/annual-report\/wp-content\/uploads\/2022\/04\/IMG_9436-300x200.jpg 300w, https:\/\/www.embl.org\/about\/info\/annual-report\/wp-content\/uploads\/2022\/04\/IMG_9436-768x512.jpg 768w, https:\/\/www.embl.org\/about\/info\/annual-report\/wp-content\/uploads\/2022\/04\/IMG_9436-1536x1024.jpg 1536w, https:\/\/www.embl.org\/about\/info\/annual-report\/wp-content\/uploads\/2022\/04\/IMG_9436-2048x1365.jpg 2048w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/>\n  <div class=\"vf-card__content | vf-stack vf-stack--400\">\n          <h3 class=\"vf-card__heading\">\n                  <a class=\"vf-card__link\" href=\"https:\/\/www.embl.org\/about\/info\/annual-report\/ar2021\/strengthening-links-to-the-biobusiness-sector\" target=\"\">\n        \n        Next Story\n                  <svg aria-hidden=\"true\" class=\"vf-card__heading__icon | vf-icon vf-icon-arrow--inline-end\" width=\"1em\" height=\"1em\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n            <path d=\"M0 12c0 6.627 5.373 12 12 12s12-5.373 12-12S18.627 0 12 0C5.376.008.008 5.376 0 12zm13.707-5.209l4.5 4.5a1 1 0 010 1.414l-4.5 4.5a1 1 0 01-1.414-1.414l2.366-2.367a.25.25 0 00-.177-.424H6a1 1 0 010-2h8.482a.25.25 0 00.177-.427l-2.366-2.368a1 1 0 011.414-1.414z\" fill=\"currentColor\" fill-rule=\"nonzero\"><\/path>\n          <\/svg>\n        <\/a>\n              <\/h3>\n    \n          <p class=\"vf-card__subheading\">Strengthening links to the biobusiness sector<\/p>\n    \n          <p class=\"vf-card__text\"><span style=\"font-weight: 400;\">New event provides a forum for sharing bioinformatics developments with BioBusiness.<\/span><\/p>\n      <\/div>\n<\/article>\n\n<\/div>\n<\/div>\n\n\n<div class=\"\"><!--[vf\/content]-->\n<div class=\"vf-content\">\n\n<article class=\"vf-card vf-card--brand vf-card--bordered vf-u-margin__bottom--800\" default>\n      <img decoding=\"async\" src=\"https:\/\/www.embl.org\/about\/info\/annual-report\/wp-content\/uploads\/2022\/06\/AR2021_PDF_mock-up_AdobeStock_182004081.jpg\" class=\"vf-card__image\" alt=\"\" loading=\"lazy\" itemprop=\"image\">\n  \n  <div class=\"vf-card__content | vf-stack vf-stack--400\">\n          <h3 class=\"vf-card__heading\">\n                  <a class=\"vf-card__link\" href=\"https:\/\/www.embl.org\/documents\/document\/annual-report-2021\/\" target=\"_blank\">\n        \n        Download the annual report summary \n                  <svg aria-hidden=\"true\" class=\"vf-card__heading__icon | vf-icon vf-icon-arrow--inline-end\" width=\"1em\" height=\"1em\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n            <path d=\"M0 12c0 6.627 5.373 12 12 12s12-5.373 12-12S18.627 0 12 0C5.376.008.008 5.376 0 12zm13.707-5.209l4.5 4.5a1 1 0 010 1.414l-4.5 4.5a1 1 0 01-1.414-1.414l2.366-2.367a.25.25 0 00-.177-.424H6a1 1 0 010-2h8.482a.25.25 0 00.177-.427l-2.366-2.368a1 1 0 011.414-1.414z\" fill=\"currentColor\" fill-rule=\"nonzero\"><\/path>\n          <\/svg>\n        <\/a>\n              <\/h3>\n    \n    \n          <p class=\"vf-card__text\">A snapshot of EMBL 2021 facts and figures<\/p>\n      <\/div>\n<\/article>\n\n<\/div>\n<\/div>\n<\/div>\n\n\n        <\/div>\n<\/section>","protected":false},"excerpt":{"rendered":"","protected":false},"author":6,"featured_media":0,"parent":38,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"vf_template_subpage.php","meta":{"_acf_changed":false,"footnotes":""},"embl_taxonomy":[],"class_list":["post-1199","page","type-page","status-publish","hentry"],"acf":[],"embl_taxonomy_terms":[],"_links":{"self":[{"href":"https:\/\/www.embl.org\/about\/info\/annual-report\/wp-json\/wp\/v2\/pages\/1199","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.embl.org\/about\/info\/annual-report\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.embl.org\/about\/info\/annual-report\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.embl.org\/about\/info\/annual-report\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.embl.org\/about\/info\/annual-report\/wp-json\/wp\/v2\/comments?post=1199"}],"version-history":[{"count":52,"href":"https:\/\/www.embl.org\/about\/info\/annual-report\/wp-json\/wp\/v2\/pages\/1199\/revisions"}],"predecessor-version":[{"id":3668,"href":"https:\/\/www.embl.org\/about\/info\/annual-report\/wp-json\/wp\/v2\/pages\/1199\/revisions\/3668"}],"up":[{"embeddable":true,"href":"https:\/\/www.embl.org\/about\/info\/annual-report\/wp-json\/wp\/v2\/pages\/38"}],"wp:attachment":[{"href":"https:\/\/www.embl.org\/about\/info\/annual-report\/wp-json\/wp\/v2\/media?parent=1199"}],"wp:term":[{"taxonomy":"embl_taxonomy","embeddable":true,"href":"https:\/\/www.embl.org\/about\/info\/annual-report\/wp-json\/wp\/v2\/embl_taxonomy?post=1199"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}